Skip to main content
. Author manuscript; available in PMC: 2012 Jun 30.
Published in final edited form as: Chem Biol Interact. 2010 Oct 21;192(1-2):145–149. doi: 10.1016/j.cbi.2010.10.008

Figure 1. The effect of compromising NQO1 on the levels of NFk-B p105 and p50 in HBMEC.

Figure 1

Treatment of HBMEC with anti-NQO1 siRNA or the mechanism-based inhibitor ES936 results in decreased levels of p105 and p50. Cells were harvested after treatment with 100nM ES936 for 2h or siRNA for 72h. (siCTL = scrambled siRNA control).